default author photo

Gerardo Baro-Roman

affiliation not provided to SSRN

SCHOLARLY PAPERS

2

DOWNLOADS

150

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Safety and Immunogenicity of Anti-SARS Cov-2 Vaccine SOBERANA 02 in Homologous or Heterologous Scheme

Number of pages: 19 Posted: 03 Dec 2021
Instituto de Medicina Tropical Pedro Kouri, affiliation not provided to SSRN, Finlay Vaccine Institute, Finlay Vaccine Institute, Institute of Cybernetics, Mathematics and Physics (ICIMAF), Finlay Vaccine Institute, Center of Molecular Immunology, Finlay Vaccine Institute, Finlay Vaccine Institute, Center of Molecular Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, Civilian Defense Scientific Research Centre, Civilian Defense Scientific Research Centre, affiliation not provided to SSRN, Immunoassay Center, affiliation not provided to SSRN, National Coordinating Center for Clinical Trials, Finlay Vaccine Institute, Finlay Vaccine Institute, Finlay Vaccine Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sichuan University, Center of Molecular Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, Finlay Vaccine Institute, Finlay Vaccine Institute, Finlay Vaccine Institute and affiliation not provided to SSRN
Downloads 120 (596,393)

Abstract:

Loading...

COVID-19, SARS-CoV-2, conjugate vaccine, heterologous immunization scheme, subunit vaccine

2.

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

Number of pages: 56 Posted: 01 Feb 2022
Instituto de Medicina Tropical Pedro Kouri, Havana Hygiene and Epidemiology Center, affiliation not provided to SSRN, affiliation not provided to SSRN, Finlay Vaccine Institute, affiliation not provided to SSRN, Finlay Vaccine Institute, Center of Molecular Immunology, Finlay Vaccine Institute, Center of Molecular Immunology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Civilian Defense Scientific Research Centre, Immunoassay Center, affiliation not provided to SSRN, National Coordinating Center for Clinical Trials, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Finlay Vaccine Institute, Finlay Vaccine Institute, affiliation not provided to SSRN, Finlay Vaccine Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, Pasteur Institute of Iran, Pasteur Institute of Iran, affiliation not provided to SSRN, Finlay Vaccine Institute, affiliation not provided to SSRN, Finlay Vaccine Institute, Finlay Vaccine Institute and Independent
Downloads 30 (1,318,317)

Abstract:

Loading...

conjugate vaccine, heterologous schedule, COVID-19, recombinant RBD, phase IIb clinical trial